title: The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modeling.
abstract: Glycyrrhizic acid is widely applied as a sweetener in food products and chewing tobacco. In addition, it is of clinical interest for possible treatment of chronic hepatitis C. In some highly exposed subjects, side effects such as hypertension and symptoms associated with electrolyte disturbances have been reported. To analyze the relationship between the pharmacokinetics of glycyrrhizic acid in its toxicity, the kinetics of glycyrrhizic acid and its biologically active metabolite glycyrrhetic acid were evaluated. Glycyrrhizic acid is mainly absorbed after presystemic hydrolysis as glycyrrhetic acid. Because glycyrrhetic acid is a 200-1000 times more potent inhibitor of 11-beta-hydroxysteroid dehydrogenase compared to glycyrrhizic acid, the kinetics of glycyrrhetic acid are relevant in a toxicological perspective. Once absorbed, glycyrrhetic acid is transported, mainly taken up into the liver by capacity-limited carriers, where it is metabolized into glucuronide and sulfate conjugates. These conjugates are transported efficiently into the bile. After outflow of the bile into the duodenum, the conjugates are hydrolyzed to glycyrrhetic acid by commensal bacteria; glycyrrhetic acid is subsequently reabsorbed, causing a pronounced delay in the terminal plasma clearance. Physiologically based pharmacokinetic modeling indicated that, in humans, the transit rate of gastrointestinal contents through the small and large intestines predominantly determines to what extent glycyrrhetic acid conjugates will be reabsorbed. This parameter, which can be estimated noninvasively, may serve as a useful risk estimator for glycyrrhizic-acid-induced adverse effects, because in subjects with prolonged gastrointestinal transit times, glycyrrhetic acid might accumulate after repeated intake.
authors.affiliation: Research Institute of Toxicology, Utrecht, The Netherlands. b.ploeger@lapp.nl
authors.forename: B
authors.initials: B
authors.lastname: Ploeger
authors.forename: T
authors.initials: T
authors.lastname: Mensinga
authors.forename: A
authors.initials: A
authors.lastname: Sips
authors.forename: W
authors.initials: W
authors.lastname: Seinen
authors.forename: J
authors.initials: J
authors.lastname: Meulenbelt
authors.forename: J
authors.initials: J
authors.lastname: DeJongh
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000900:Anti-Bacterial Agents / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics / Q000633:toxicity; D000893:Anti-Inflammatory Agents / Q000097:blood / Q000378:metabolism / Q000633:toxicity; D004064:Digestive System / Q000378:metabolism / Q000382:microbiology; D006034:Glycyrrhetinic Acid / Q000097:blood / Q000378:metabolism / Q000633:toxicity; D006035:Glycyrrhiza / Q000737:chemistry*; D019695:Glycyrrhizic Acid / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use / Q000633:toxicity; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D008099:Liver / Q000378:metabolism; D008954:Models, Biological; D015394:Molecular Structure
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D019695:Glycyrrhizic Acid; D006034:Glycyrrhetinic Acid